Major Thalassemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: The second group received exjade pills 20 mg/kg daily. Starfax device was used to measure ferritin serum at the beginning of the study and every 3 month during a 6-month period. Interv
Treatment - Drugs
The second group received exjade pills 20 mg/kg daily. Starfax device was used to measure ferritin serum at the beginning of the study and every 3 month during a 6-month period.
The first group received the normal treatment including 40 mg/kg deferoxamine hypodermic daily for 6 days a week. Starfax device was used to measure ferritin serum at the beginning of the study and ev
The third group was treated with daily injection of 40 mg/kg of deferoxamine hypodermic 3 days a week and exjade pill 10mg/kg was taken simultaneously. Starfax device was used to measure ferritin seru
Sponsors
Kermanshahu University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: Inclusion: being younger than 18; having thalasemia major based on observing clinical symptoms and hemoglobin electrophoresis history; being treated by deferoxamine hypodermic injection and ferritin level 1000 to 3000. Exclusion:inability to digest exjade; hepatitis virologic; LFT; active hepatitis; noncompliance with previous treatment regimens; ALT and AST normal up to 3 times
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ferritin serum amount. Timepoint: at the beginning of the study and every 3 month for 6 months. Method of measurement: Using starfax device. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed